Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models

Stem Cells Translational Medicine

Volumn 2, Issue 3, 2013, Pages 233-242

  Zhang, Cathy C ^a   Yan, Zhengming ^a   Zong, Qing ^a   Fang, Douglas D ^a   Painter, Cory ^a   Zhang, Qin ^a   Chen, Enhong ^a   Lira, Maruja E ^a   John Baptiste, Annette ^a   Christensen, James G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Breast cancer; FACS; Stem cell; Stem cell transplantation

Indexed keywords

CELL SURFACE MARKER; DOCETAXEL; PF 3084014; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER GRAFT; CELL SUBPOPULATION; DRUG POTENTIATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; METASTASIS POTENTIAL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACODYNAMICS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84875101176     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0096     Document Type: Article

References (47)

1. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-351.
2. Cheng L, Alexander R, Zhang S et al. The clinical and therapeutic implications of cancer stem cell biology. Expert Rev Anticancer Ther 2011;11:1131-1143.
3. Wang Z, Li Y, Kong D et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the Notch signaling pathway. Cancer Res 2009;69:2400-2407.
4. Cho S, Lu M, He X et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA 2011;108:20778-20783.
5. Chen Y, Li D, Liu H et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther 2011;11:14-21.
6. Mungamuri SK, Yang X, Thor AD et al. Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-4724.
7. Jiao Z, Wang W, Ma J et al. Notch signaling mediates TNF-α-induced IL-6 production in cultured fibroblast-like synoviocytes from rheumatoid arthritis. Clin Dev Immunol 2012; 2012:350209.
8. Wang H, Holloway MP, Ma L et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010;285:36129-36137.
9. Conze D, Weiss L, Regen PS et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001;61:8851-8858.
10. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-646.
11. Sansone P, Storci G, Tavolari S et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117: 3988-4002.
12. Takebe N, Harris PJ, Warren RQ et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106.
13. Wright M, Calcagno A, Salcido C et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
14. Grudzien P, Lo S, Albain KS et al. Inhibition of notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 2010;30:3853-3867.
15. Farnie G, Clarke RB. Mammary stem cells and breast cancer: Role of notch signalling. Stem Cell Rev 2007;3:169-175.
16. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-679.
17. Phillips TM, McBride WH, Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785.
18. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
19. Honeth G, Bendahl PO, Ringnér M et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
20. Sheridan C, Kishimoto H, Fuchs RK et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006; 8:R59.
21. Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615-5621.
22. Ricardo S, Vieira AF, Gerhard R et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64:937-946.
23. Zhou B-BS, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
24. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-177.
25. Kondratyev M, Kreso A, Hallett RM et al. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 2012;31:93-103.
26. Gilbert CA, Daou M-C, Moser RP et al. γ-Secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70:6870-6879.
27. Meng RD, Shelton CC, Li YM et al. γ-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009;69:573-582.
28. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: Enriching for cells with functional properties in mice or in man? Breast Cancer Res 2007;9:303.
29. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
30. Croker AK, Goodale D, Chu J et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009;13:2236-2252.
31. Wei P, Walls M, Qiu M et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010;9:1618-1628.
32. Zhang CC, Pavlicek A, Zhang Q et al. Biomarker and pharmacological evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res 2012;18:5008-5019.
33. Hwang-Verslues WW, Kuo WH, Chang PH et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009;4: e8377.
34. Zhang C, Yan Z, Arango ME et al. Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 2009;15:238-246.
35. Rao SS, O'Neil J, Liberator CD et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 2009;69:3060-3068.
36. Luistro L, He W, Smith M et al. Preclinical profile of a potent γ-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-7680.
37. Chapman G, Liu L, Sahlgren C et al. High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol 2006;175:535-540.
38. Konishi J, Yi F, Chen X et al. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2010;29:589-596.
39. Lee CW, Simin K, Liu Q et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008;10:R97.
40. Crea F, Duhagon-Serrat MA, Hurt EM et al. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 2011;128:1946-1954.
41. Pannuti A, Foreman K, Rizzo P et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-3152.
42. Naumov GN, Townson JL, MacDonald IC et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82:199-206.
43. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106: 13820-13825.
44. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-497.
45. Shi C, Tian R, Wang M et al. CD44+ CD133+ population exhibits cancer stem celllike characteristics in human gallbladder carcinoma. Cancer Biol Ther 2010;10:1182-1190.
46. Nguyen LV, Vanner R, Dirks P et al. Cancer stem cells: An evolving concept. Nat Rev Cancer 2012;12:133-143.
47. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007;117: 3660-3663.